Bio-Rad Laboratories Balances Growth Hopes With Margin Strain

Bio-Rad Laboratories ((BIO)) has held its Q4 earnings call. Read on for the main highlights of the call.

Bio-Rad Laboratories’ latest earnings call struck a cautious but not pessimistic tone. Management highlighted solid cash generation, a rebound in Clinical Diagnostics, and momentum in digital PCR, while also acknowledging margin pressure, execution missteps in supply chain, and softness in parts of the Life Science portfolio that weighed on profitability.

Q4 Revenue Growth and Full-Year Stability

Bio-Rad posted Q4 2025 net sales of $693 million, up 3.9% reported and 1.7% on a currency-neutral basis versus the prior year. Full-year 2025 sales were $2.583 billion, up 0.7% reported and essentially flat in constant currency, underscoring a business that is stabilizing but not yet back to robust growth.

Diagnostics Segment Returns to Growth

Clinical Diagnostics was a clear bright spot with Q4 sales of about $425 million, rising 8.4% reported and 5.6% currency-neutral year over year. Growth was driven by quality control and blood typing products, helping full-year Diagnostics sales increase 1.6% reported and 0.8% on a currency-neutral basis.

ddPCR Strength and QX700 Uptake

The ddPCR portfolio delivered mid-single-digit growth in Q4, supported by a strong ramp in QX700 instrument sales that expanded the order funnel heading into 2026. Management positioned ddPCR as a core long-term growth pillar and expects the platform to sustain mid-single-digit growth next year.

Stilla Deal Turning Accretive Earlier

The Stilla acquisition is tracking ahead of plan with management now expecting it to be accretive by mid-2026, six to twelve months earlier than originally guided. Stilla contributed revenue in the mid-single-digit millions during Q4, reinforcing confidence in the strategic fit of the transaction.

Robust Cash Generation and Free Cash Flow

Cash performance was a major positive, with Q4 operating cash flow rising to $165 million from $124 million a year earlier. For 2025, operating cash flow reached $532 million, driving free cash flow to roughly $375 million and yielding a strong 138% conversion versus non-GAAP net income.

Balance Sheet Strength and Buybacks

Bio-Rad closed the year with $1.541 billion in cash and short-term investments, giving it ample financial flexibility. The company repurchased 1.2 million shares in 2025 for about $296 million and has bought back 1.9 million shares since early 2024, reducing the share count by around 6.6% with $285 million still authorized.

Process Chromatography’s 2025 Surge

Management noted that process chromatography delivered more than 20% growth in 2025, reflecting demand tied to select commercial therapeutics and vaccines. They cautioned that this business is inherently lumpy and concentrated, a dynamic that investors should expect to continue.

Guidance Highlights for 2026

For 2026, Bio-Rad guided to 0.5%–1.5% currency-neutral revenue growth with Q1 declining low single digits before improving through the year. The company expects non-GAAP gross margin of 54%–54.5%, operating margin of 12%–12.5%, and free cash flow between $375 million and $395 million.

Gross Margin Pressures and Supply Chain Costs

Q4 2025 GAAP gross margin fell to 49.8% from 51.2%, while non-GAAP gross margin slipped to 52.5% from 53.9%, reflecting cost pressures. Management cited elevated expedited freight, overtime, and supply chain costs tied to compressed delivery timelines and slower-than-planned procurement savings.

GAAP Operating Loss and Impairments

The company reported a GAAP operating loss of about $119 million in Q4 compared with $58 million of operating income a year earlier. Results were hit by roughly $173 million in impairment charges related to purchased intangibles and other items stemming from R&D reprioritization and portfolio rationalization.

Non-GAAP Profitability Under Strain

Non-GAAP operating margin declined to 12% in Q4 from 13.8% the prior year, and non-GAAP net income dropped to $68 million or $2.51 per diluted share. For 2025, non-GAAP operating margin slipped to 12.1% from 12.9%, with non-GAAP net income falling to $271 million or $9.92 per share.

Life Science Softness and Chromatography Headwinds

Life Science remains challenged with Q4 sales of $268 million, down 2.6% reported and 4% currency-neutral year over year. Management expects process chromatography to decline about mid-teens in 2026 due to regulatory changes and customer efficiencies, though core Life Science excluding that line is guided to grow nearly 4%.

Rising SG&A and Cost Pressures

Selling, general, and administrative expenses rose to $221 million in Q4 from $204 million, increasing as a percentage of sales to 31.9%. On a non-GAAP basis, SG&A climbed to $215 million from $200 million, largely due to higher employee-related costs that weighed on operating leverage.

One-Time Write-Offs Weigh on Margins

Q4 non-GAAP gross margin excluded about $13 million in one-time inventory and related write-offs associated with portfolio pruning. These charges came on top of restructuring and amortization expenses tied to purchased intangibles, highlighting the cost of Bio-Rad’s ongoing product rationalization efforts.

End-Market Demand Headwinds

Management pointed to continued cautious spending in academic and government markets, which dampened instrument demand. While biopharma funding has improved, it remains skewed toward later-stage firms, limiting a broader recovery for core Life Science customers.

Equity Valuation Volatility Distorts GAAP Net Income

Q4 reported net income surged to $720 million, or $26.65 per diluted share, driven by an $800 million gain from revaluing shares in Sartorius AG. Executives stressed that non-GAAP metrics strip out this equity volatility to better reflect underlying operating performance.

Forward-Looking Guidance and Outlook

For 2026, Bio-Rad expects modest top-line growth, with Diagnostics advancing 1%–2% and core Life Science ex-process chromatography growing around 4% while chromatography itself falls mid-teens. Management plans to hold non-GAAP operating margins in the 12%–12.5% range, generate up to $395 million in free cash flow, and continue using its strong balance sheet and buyback capacity to support shareholder returns.

Bio-Rad’s earnings call painted a balanced picture of a company with strong cash flow, valuable growth platforms in Diagnostics and ddPCR, and a solid balance sheet, yet facing margin and execution pressures. Investors will be watching closely to see whether management can convert its conservative 2026 plan into steady growth while smoothing out volatility in Life Science and restoring profitability momentum.